Shattuck Labs Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Good afternoon everybody. Welcome to our fireside with Shattuck. Thanks, Taylor, for joining us. We're very excited to get into the nitty-gritty here, but why don't I start by Taylor giving you an opportunity to intro the platform a little bit. Can you tell us a little bit about your ARCs and your approach to immunostimulation?
Sure. Hi Jon, Hi Eric, thanks for the invitation. So the agonist redirected checkpoint or ARC platform is a two-sided Fc-fusion protein platform where one end of these molecules is aimed at blocking different immune checkpoints and the other end is aimed at activating co-stimulatory receptors in the TNF superfamily.
To do that well, these molecules need to -- any TNF receptor agonist really needs to attain at least a trimeric, but even better if it's a hexameric configuration. That's something that we've learned through over 20 years of Phase 1 trials with monoclonal antibodies going after targets like CD40 that just have not
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |